TP53 and cancer: Importantly, a small subset of Li-Fraumeni syndrome patients harbor genomic deletions in the TP53 locus and cancers that develop in dominant-negative, heterozygous point-mutation carriers often display deletion of the second TP53 allele (Malkin, 2011).